Verici still awaits the Local Coverage Determination (LCD) decision required for Tutivia reimbursement, but Management confirms expectations for an outcome imminently. Whilst the company cannot yet recognise revenues, adoption momentum continues with 292 tests ordered in 1Q25 (68% QoQ increase). Additionally, with Thermo’s investment in new research for PTRA, and the prospect of licensing deals and collaborations impacted by market challenges, total revenues for FY25E are now expected to be $4.4 ....
